Emcure Pharmaceuticals Limited — Updates, 21-06-2025: Press Release

Emcure Pharmaceuticals has announced a board meeting to approve acquiring the remaining 20.42% stake in its subsidiary Zuventus Healthcare Ltd. Post-transaction, Zuventus will be a 100% subsidiary, enabling full financial consolidation and operational synergy. This move strengthens Emcure’s focus on the domestic market and aims to enhance long-term value by aligning its domestic businesses.